Evidence map›Paper›PMID 26887611›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2016

Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.

K Zhang, H Yao, Z Yang, D Li, L Yang, Q Zou, Y Yuan, X Miao

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

K ZhangDepartment of General Surgery, The Fourth People's Hospital of Changde, Changde, 415000, Hunan, People's Republic of China.
H YaoDepartment of General Surgery, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China. yaohongliang08@outlook.com.
Z YangResearch Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China.
D LiDepartment of Pathology, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China.
L YangResearch Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China.
Q ZouDepartment of Pathology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, People's Republic of China.
Y YuanDepartment of Pathology, Third Xiangya Hospital, Central South University, Changsha, 410013, Hunan, People's Republic of China.
X MiaoResearch Laboratory of Hepatobiliary Diseases, Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China.
Second Xiangya Hospital of Central South University · CNCentral South University · CNThe Fourth People's Hospital · CNThird Xiangya Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor of the pancreas with poor prognosis. The lack of understanding of the molecular mechanisms of PDAC and biomarkers for early diagnosis might be two of the reasons for the poor prognosis of PDAC. MATERIALS AND

methodsILK and ERP29 protein expressions in PDAC, peritumoral tissues, benign pancreatic lesions, and normal pancreatic tissues were measured by immunohistochemistry and the clinical and pathological significances of ILK and ERP29 in PDAC were analyzed.

resultsThe percentages of positive ILK and negative ERP29 expressions were significantly higher in PDAC tumors than in peritumoral tissues, benign pancreatic tissues, and normal pancreatic tissues (P < 0.01). Benign pancreatic lesions with positive ILK and negative ERP29 expressions exhibited dysplasia or intraepithelial neoplasia. The percentage of cases with positive ILK and negative ERP29 expressions was significantly lower in PDAC patients without lymph node metastasis and invasion, and having TNM stage I/II disease than in patients with lymph node metastasis, invasion, and TNM stage III/IV disease (P < 0.05 or P < 0.01). Kaplan-Meier survival analysis showed that positive ILK and negative ERP29 expressions were significantly associated with survival in PDAC patients (P < 0.001). Cox multivariate analysis revealed that positive ILK and negative ERP29 expressions were independent poor prognosis factors in PDAC patients.

conclusionsPositive ILK and negative ERP29 expressions are associated with the progression of PDAC and poor prognosis in patients with PDAC.

Indexed as

AdenocarcinomaBiomarkers, TumorCarcinoma, Pancreatic DuctalDisease ProgressionFemaleFollow-Up StudiesHeat-Shock ProteinsHumansImmunoenzyme TechniquesLymphatic MetastasisMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPancreatic NeoplasmsPrognosisBiomarkers, TumorERP29 protein, humanHeat-Shock ProteinsProtein Serine-Threonine KinasesScaffold Protein ILKChronic pancreatitisERP29ILKImmunohistochemistryPancreatic ductal adenocarcinomaPancreatic intraepithelial neoplasia

Identifiers

PMID26887611
OpenAlexW2277832635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.